Machine Learning in Atrial Fibrillation

Description

Atrial fibrillation is a serious public health issue that affects over 5 million Americans (Miyazaka, Circulation 2006) in whom it may cause skipped beats, dizziness, stroke and even death. Therapy for AF is currently suboptimal, in part because AF represents several disease states of which few have been delineated or used to successfully guide management. This study seeks to clarify this delineation of AF types using machine learning (ML).

Conditions

Atrial Fibrillation, Arrhythmias, Cardiac

Study Overview

Study Details

Study overview

Atrial fibrillation is a serious public health issue that affects over 5 million Americans (Miyazaka, Circulation 2006) in whom it may cause skipped beats, dizziness, stroke and even death. Therapy for AF is currently suboptimal, in part because AF represents several disease states of which few have been delineated or used to successfully guide management. This study seeks to clarify this delineation of AF types using machine learning (ML).

Machine Learning in Atrial Fibrillation

Machine Learning in Atrial Fibrillation

Condition
Atrial Fibrillation
Intervention / Treatment

-

Contacts and Locations

Stanford

Stanford University, Stanford, California, United States, 94305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * undergoing ablation at Stanford of (a) paroxysmal AF (self-terminates \< 7 days), or (b) persistent AF (requires cardioversion to terminate).
  • * Per our clinical practice and guidelines (Calkins et al, Heart Rhythm 2012), patients will have failed or be intolerant of ≥ 1 anti-arrhythmic drug.
  • * active coronary ischemia or decompensated heart failure
  • * atrial or ventricular clot on trans-esophageal echocardiography
  • * pregnancy (to minimize fluoroscopic exposure)
  • * inability or unwillingness to provide informed consent
  • * rheumatic valve disease (results in a unique AF phenotype)
  • * thrombotic disease or venous filters

Ages Eligible for Study

22 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Study Record Dates

2026-12